Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies

ConclusionThe present meta-analysis demonstrated that for cancer-free adults aged 50  years or older with osteoporosis, denosumab was as safe as zoledronic acid for the risk of drug-induced fractures. However, denosumab had a lower incidence of composite cardiovascular disease, and may be a better option for the population with cardiovascular disease. Nonetheless, due to limitation s like a short-term follow-up, gender, and incomplete types of adverse effects, more randomized controlled trials (RCTs) are required to further verify this conclusion.
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research